Navigation Links
ShangPharma Appoints Pharmaceutical Executive Dr. Mitchell Reff Chief Biologics Officer
Date:1/13/2014

SHANGHAI, Jan. 13, 2014 /PRNewswire/ -- ShangPharma Corporation is pleased to announce that Dr. Mitchell Reff has joined the company as Chief Biologics Officer. Dr. Reff brings over 30 years of research and development experience in the biopharmaceutical industry. Dr. Reff's appointment further strengthens the world-class technical capabilities of ChemPartner's Biologics Division and offers Pharmaceutical and Biotechnology companies from around the world first-rate strategic and technical expertise to discover and manufacture novel first-in-class and best-in-class biologic clinical development candidates to advance into the Pharmaceutical and Biotechnology company pipelines.

Dr. Reff received his Ph.D. in Medical Microbiology from Stanford University School of Medicine, and his Bachelor's degree in Chemistry from Massachusetts Institute of Technology. This was followed by a  Postdoctoral Fellowship at Harvard Medical School, and  a position at the National Cancer Institute. Dr. Reff then spent 8 years at SmithKline Laboratories working on gene expression in mammalian cells and protein engineering. After that, he joined Idec Pharmaceuticals as head of molecular biology in 1990. Dr. Reff had a distinguished 21 year career at Idec, and later at Biogen Idec. He was Vice President Discovery Oncology at Biogen Idec running multiple bicoastal oncology groups developing small molecule and recombinant protein therapeutic molecules for oncology and delivered 6 novel oncology drugs into clinical trials in 5 years.

In early 1990s, Dr. Reff was Project Leader targeting B cell lymphoma, building and expressing the chimeric mouse-human anti-CD20 monoclonal antibody (Rituxan), the first monoclonal antibody approved to treat a tumor. Dr. Reff led the efforts from discovery until Rituxan entered its pivotal clinical trial.

Dr. Reff is well-recognized in the pharmaceutical and research community having been listed as an inventor on approximately 29 patents and patent applications, and as an author in nearly 100 scientific publications and presentations.

About ShangPharma:

ShangPharma Corp is a leading contract research organization (CRO) providing a broad range of high-quality, integrated services across both drug discovery and drug development to help pharmaceutical and biotechnology companies discover and develop novel drug candidates efficiently. The Company today has a team of nearly 2,000 skilled scientists in 1 million square feet of state-of-the-art research facilities and office space. For more information, please visit: http://www.ShangPharma.com. ChemPartner is a wholly owned subsidiary of ShangPharma Corp and also the main brand of the group.


'/>"/>
SOURCE ShangPharma
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. ShangPharma Corporation Announces Completion of Merger
2. ShangPharma Corporation Announces Extraordinary General Meeting of Shareholders
3. ShangPharma Announces Third Quarter 2012 Results
4. ShangPharma to Report Third Quarter 2012 Financial Results on November 20, 2012
5. ShangPharma and Harbour Antibodies Announce Licensing Agreement
6. ShangPharma Announces Second Quarter 2012 Results
7. ShangPharma to Report Second Quarter 2012 Financial Results on August 20, 2012
8. ShangPharma Independent Committee Appoints Financial Advisor
9. ShangPharma Independent Committee Appoints Chairman and Legal Counsel
10. ShangPharma Announces Receipt of "Going Private" Proposal at $8.50 to $9.50 Per ADS
11. ShangPharma Announces First Quarter 2012 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2017)... division of Diplomat Specialty Infusion Group, is celebrating a decade of empowering ... celebrate its anniversary, ThriveRx recently launched a redesigned website at thriverx.diplomat.is ... to create the best user experience for consumers and health care professionals. ... Diplomat Pharmacy ... "We,ve made several great strides throughout the past 10 years," ...
(Date:7/5/2017)... Oramed Pharmaceuticals Inc. (NASDAQ: ... a clinical-stage pharmaceutical company focused on the development of oral ... from the Israel Securities Authority to dual-list its common stock ... will commence trading on the TASE on July 12, 2017 ... of the Company, it is expected that Oramed will be ...
(Date:7/5/2017)... Wash. , July 5, 2017   BioLife ... leading developer, manufacturer and marketer of proprietary clinical grade ... cryopreservation freeze media ("BioLife"), today announced that it ... its debt holder and largest shareholder, to modify its ... Pursuant to the modification, WAVI agreed to exchange ...
Breaking Medicine Technology:
(Date:7/21/2017)... ... July 21, 2017 , ... Sharon Kleyne ... signature product of her research center at Bio-Logic Aqua Research® Water Life Science®, ... the greatest number of sufferers of blindness. “We think that Nature’s Tears® EyeMist® ...
(Date:7/21/2017)... TORONTO, ONTARIO, CANADA (PRWEB) , ... July 21, ... ... may give insight into why concussion rates are on the rise, say researchers ... Annual Meeting today in Toronto, Ontario, Canada. , “The combination of evaluating the ...
(Date:7/20/2017)... ... July 20, 2017 , ... ... enterprise-grade IT operations analytics and application performance monitoring (APM) solutions, has expanded ... healthcare services providers. , According to Peter Ohrenberger, sales director at Nastel, ...
(Date:7/20/2017)... ... July 20, 2017 , ... Team Type 1 Foundation, a ... for everyone affected by diabetes, is teaming up with a Microsoft Corp. employee-led hackathon ... off on July 24th. , “Team Type 1’s mission overlaps seamlessly with Microsoft’s ...
(Date:7/20/2017)... ... July 20, 2017 , ... Using CDRH’s Medical Device ... — 1:30 p.m. – 3:00 p.m. ET, http://www.fdanews.com/mdqualitydata          , Device makers ... It’s known as the “CY2016 Annual FDA Medical Device Quality System Data” report. ...
Breaking Medicine News(10 mins):